Sort   by:  
 Page size 
UnknownAwareness of respiratory syncytial virus and other respiratory disease vaccines among healthcare professionals and their patients in Italy: Insights from a literature review and a web-based survey.
Respiratory syncytial virus (RSV) causes respiratory infections across all ages, with an increasingly recognized burden in older adults, particularly those with comorbidities. Despite the recent licensure of RSV vaccines, awareness of RSV and other respiratory disease vaccinations remains limited. W...
S-EPMC12413043 | biostudies-literature
UnknownAtypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective.

Background

Empirical antibiotic coverage for atypical pathogens in community-acquired pneumonia (CAP) has long been debated, mainly because of a lack of epidemiological data. We aimed to assess both testing for atypical pathogens and their prevalence in hospitalized patients with CAP worldwi...
S-EPMC6299604 | biostudies-literature
UnknownImpact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the i...
S-EPMC10112941 | biostudies-literature
UnknownNirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.

Background

Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the lat...
S-EPMC10078172 | biostudies-literature
UnknownBacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study.
An accurate knowledge of the epidemiology of community-acquired pneumonia (CAP) is key for selecting appropriate antimicrobial treatments. Very few etiological studies assessed the appropriateness of empiric guideline recommendations at a multinational level. This study aims at the following: (i) de...
S-EPMC7222990 | biostudies-literature
UnknownTreatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies.

Background

Community-acquired pneumonia (CAP) guidelines have improved the treatment and outcomes of patients with CAP, primarily by standardization of initial empirical therapy. But current society-published guidelines exclude immunocompromised patients.

Research question

There is no...
S-EPMC7297164 | biostudies-literature
UnknownBreakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2...
S-EPMC9492383 | biostudies-literature
UnknownPrevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients.

Background

The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia.

Methods

We conducted a secondary analysis of an internation...
S-EPMC6481991 | biostudies-literature
UnknownCOVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).

Background

Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM p...
S-EPMC8515781 | biostudies-literature
UnknownUse of isavuconazole in critically ill patients in intensive care units: a prospective, observational, multicentre, cohort study.

Objectives

In this multicentre, prospective study, we aimed to describe the use of isavuconazole in critically ill adult patients in ICU, in terms of patient characteristics, infection characteristics and outcomes.

Methods

Prospective, observational study of ICU patients treated with ...
S-EPMC12498522 | biostudies-literature
Sort   by:  
 Page size